Sep 14, 2018, 01:00 by admin admin

ASAM submitted comments regarding SAMHSA's Supplemental Notice of Proposed Rulemaking (SNPRM) on the Confidentiality of Substance Use Disorder Patient Records (42 CFR part 2).

Sep 14, 2018, 01:00 by admin admin

ASAM and the New Jersey Society of Addiction Medicine (NJSAM) submitted letters of support with recommended revision for A4138 and S1051, legislation that would require state insurance providers to cover the costs of buprenorphine and prohibit utilization controls.

Sep 14, 2018, 01:00 by admin admin

The American Society of Addiction Medicine (ASAM) and the American Medical Association (AMA) jointly announced today the release of a concept paper detailing a groundbreaking alternative payment model (APM) that could revolutionize how patients with opioid use disorder are treated.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted comment letters to the Food and Drug Administration (FDA) with recommendations regarding its proposed Blueprint for the extended-release, long-acting (ER/LA) Opioid Risk Evaluation and Mitigation Strategy (REMS) training as well as whether such training should be mandatory for all ER/LA opioid prescribers.

Sep 14, 2018, 01:00 by admin admin

ASAM signed onto a letter sent to the Senior Advisor to the President regarding the Office of Management and Budget's (OMB) proposed budget which would slash funding for the Office of National Drug Control Policy (ONDCP) and drug control program funding.

Sep 14, 2018, 01:00 by admin admin

ASAM and the New York Society of Addiction Medicine (NYSAM) submitted comments on emergency proposed regulations to align state law with federal law to allow NPs and PAs to prescribe buprenorphine for addiction treatment.

Sep 14, 2018, 01:00 by admin admin

ASAM submitted recommendations on the White House Opioid Commission’s Interim Report. The Interim Report outlines recommendations from the commission to inform the White House of the best methods to combat the opioid epidemic.

Sep 14, 2018, 01:00 by admin admin

ASAM issued a letter of support for H.R. 4097, the Medicare Beneficiary Opioid Addiction Treatment Act, sponsored by Rep. Richard Neal. This legislation would modify the Medicare Part B program to permit Medicare coverage of methadone as an outpatient treatment for addiction. Currently, Medicare only covers methadone for inpatient use when used for addiction and is contrary to ASAM’s policy recommending that all public and private payers provide insurance coverage for the treatment of opioid addiction.

Sep 14, 2018, 01:00 by admin admin

ASAM led a coalition letter to HHS Secretary Tom Price expressing concern about comments he made in West Virginia suggesting that some forms of medication for opioid use disorder are superior to others, and that some are just replacing one opioid with another. The letter emphasizes how all three medications r approved by the FDA to treat opioid use disorder and are safe, effective, and help patients enter and sustain recovery and regain control of their lives.

Oct 3, 2017, 01:00 by admin admin

Newest update on opioid addiction- calls for a cultural shift in the way Americans talk about the opioid overdose crisis and recommends actions that can prevent and treat opioid use disorder and promote recovery.